Bullish & Foolish
Full PPCB fundamentals All 466 on the Survival Watch

PPCBPROPANC BIOPHARMA, INC.

Is Propanc Biopharma struggling financially?

Yes, by its own account. Propanc Biopharma told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

0/100

Critical

Sector
Biotech/Pharma
Market cap
$3.8M
Source filing
10-Q 14 May 2026
Balance sheet
31 Mar 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What Propanc Biopharma told the SEC

…4,080,653 . Additionally, as of March 31, 2026, the Company had accumulated deficit of $ 140,843,234 . It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report. The unaudited condensed consolidated financial statements do not include any adjustments to reflect…

PROPANC BIOPHARMA, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 1024.7% share-count increase The company issued stock. Each share now owns 91.1% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -1021.7x the interest bill, so the interest is being met out of cash reserves rather than out of the business.

Other Biotech/Pharma companies that filed the doubt